In October 2024, the largest clinical trial into tDCS in the UK and US was published by the authoritative Nature Medicine.

Patients who used Flow for 10-weeks were about twice as likely to see their depression go into remission than those in a control group who performed the same procedure with the current switched off.

The placebo-controlled RCT is considered the gold standard method for evaluating efficacy and was carried out by Kings College London, the University of East London and UTHealth Houston.

Source: Woodham, R.D., Selvaraj, S., Lajmi, N. et al. Nat Med (2024).